- Stocks
- Pharma & Healthcare
- Titan Biotech
Titan Biotech share price
NSE: TITANBIOPharma & HealthcareBiotechnology
Titan Biotech at a glance
With a market capitalisation of ₹1,793 Cr, it ranks 1195th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.
Its return on equity was 16.5% in FY26. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹49 Cr (+38.8% year on year) and net profit ₹7 Cr (+74.0%), on a consolidated basis. Promoters held 55.78% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹1,793 CrRank 1195 on NSE
- Price to book
- 10.42×FY26
- EPS (TTM)
- ₹29.65to Q4 FY26
- ROE
- 16.5%FY26
- ROCE
- 20.8%FY26
- Debt to equity
- 0.02FY26
- Net profit margin
- 13.3%FY26
- Book value / share
- ₹43.94FY26
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Titan Biotech quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹43 Cr | ₹40 Cr | ₹38 Cr | ₹35 Cr | ₹47 Cr | ₹54 Cr | ₹57 Cr | ₹49 Cr |
| Revenue YoY | +24.1% | −8.2% | −16.7% | −11.9% | +7.9% | +36.2% | +47.6% | +38.8% |
| Net profit | ₹6 Cr | ₹5 Cr | ₹4 Cr | ₹4 Cr | ₹6 Cr | ₹7 Cr | ₹8 Cr | ₹7 Cr |
| Net profit YoY | +5.4% | −17.1% | −48.5% | −22.1% | +8.1% | +37.2% | +107.1% | +74.0% |
| Net margin | 13.2% | 12.5% | 9.9% | 10.7% | 13.2% | 12.6% | 13.9% | 13.4% |
| EPS | ₹7.74 | ₹8.10 | ₹5.31 | ₹4.90 | ₹8.30 | ₹9.40 | ₹10.32 | ₹1.63 |
Titan Biotech financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹142 Cr | ₹153 Cr | ₹144 Cr | ₹164 Cr | ₹156 Cr | ₹206 Cr |
| Operating profit | ₹43 Cr | ₹38 Cr | ₹28 Cr | ₹32 Cr | ₹24 Cr | ₹38 Cr |
| Net profit | ₹32 Cr | ₹29 Cr | ₹21 Cr | ₹24 Cr | ₹18 Cr | ₹27 Cr |
| EPS (₹) | ₹37.00 | ₹31.00 | ₹25.00 | ₹30.00 | ₹26.00 | ₹7.00 |
| Cash from operations | ₹19 Cr | ₹23 Cr | ₹21 Cr | ₹21 Cr | ₹20 Cr | ₹30 Cr |
| Total debt | ₹5 Cr | ₹8 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹69 Cr | ₹99 Cr | ₹110 Cr | ₹133 Cr | ₹153 Cr | ₹182 Cr |
Titan Biotech shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 55.88% | 55.88% | 55.78% | 55.78% | 55.78% | 55.78% |
| Domestic institutions | 0.01% | 0.03% | 0.03% | 0.03% | 0.03% | 0.01% |
| Non-institutions | 44.11% | 44.09% | 44.19% | 44.19% | 44.19% | 44.21% |
Titan Biotech vs peers
The listed Pharma & Healthcare companies nearest to Titan Biotech by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| HESTERBIOHester Biosciences | ₹2,280.00 | +1.97% | +31.4% | ₹1,940 Cr | 33.7 | — |
| BETABeta Drugs | ₹1,736.30 | −3.00% | +0.3% | ₹1,925 Cr | 42.5 | — |
| FISCHERFischer Medical Ventures | ₹28.21 | −3.56% | −71.0% | ₹1,846 Cr | 62.7 | — |
| WINDLASWindlas Biotech | ₹892.20 | −2.24% | −2.1% | ₹1,841 Cr | 28.6 | — |
| TITANBIOTitan Biotech | — | — | — | ₹1,793 Cr | — | — |
| NGLFINENGL Fine-Chem | ₹2,755.30 | −0.53% | +80.1% | ₹1,702 Cr | 35.3 | — |
| KRSNAAKrsnaa Diagnostics | ₹515.00 | −3.67% | −38.4% | ₹1,671 Cr | 16.7 | — |
Ask anything about Titan Biotech
Pivot answers on the live chart with evidence you can check, and tests strategies against TITANBIO's own history. Try: “Why has TITANBIO moved over the last three months?” · “Backtest a 50-day moving-average crossover on TITANBIO over five years” · “Compare TITANBIO with HESTERBIO on margins and valuation”
Frequently asked questions about Titan Biotech
What is the market cap of Titan Biotech?
Titan Biotech's market capitalisation is ₹1,793 Cr (₹1,793 Cr) at the 19 Oct 2026 close, ranking 1195th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Titan Biotech?
Return on equity was 16.5% in FY26 and return on capital employed was 20.8% in FY26 (consolidated figures).
Is Titan Biotech a debt-free company?
Titan Biotech is close to debt-free: its debt-to-equity ratio was 0.02 in FY26.
What were Titan Biotech's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Titan Biotech reported revenue of ₹49 Cr, +38.8% year on year, and net profit of ₹7 Cr, +74.0% year on year.
What is the shareholding pattern of Titan Biotech?
As of 30 Jun 2026: promoters 55.78%, domestic institutions 0.01%, non-institutions 44.21%.
Who are Titan Biotech's competitors?
The listed Pharma & Healthcare companies closest to Titan Biotech by market cap are Hester Biosciences, Beta Drugs, Fischer Medical Ventures, Windlas Biotech, NGL Fine-Chem and Krsnaa Diagnostics.
Is Titan Biotech a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Titan Biotech's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on TITANBIO against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with T · all NSE stocks · this page as text